Gilead Sciences Gestione
Criteri Gestione verificati 2/4
Gilead Sciences Il CEO è Dan O'Day, nominato in Mar2019, e ha un mandato di 7.25 anni. la retribuzione annua totale è $ 28.44M, composta da 6.3% di stipendio e 93.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.05% delle azioni della società, per un valore di $ 77.87M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.1 anni e 6.4 anni.
Informazioni chiave
Dan O'Day
Amministratore delegato
US$28.4m
Compenso totale
| Percentuale dello stipendio del CEO | 6.31% |
| Mandato del CEO | 7.3yrs |
| Proprietà del CEO | 0.05% |
| Durata media del management | 6.1yrs |
| Durata media del Consiglio di amministrazione | 6.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Jun 23
Gilead Sciences: The Market Is Underestimating Its Growth Runway
Summary Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy. GILD maintains a strong A- rated balance sheet, low leverage, and a well-covered 2.65% dividend, supporting future strategic flexibility. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Jun 12
GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings
Analyst price targets for Gilead Sciences have been refined to $180.00, with updated assumptions reflecting slightly lower revenue growth, a modestly higher profit margin, a small reduction in the discount rate, and a marginally lower future P/E, as analysts balance enthusiasm for assets like Trodelvy, Yeztugo, lenacapavir, and the Tubulis platform against more cautious long term expectations. Analyst Commentary Recent Street research shows a mix of enthusiasm and caution around Gilead, with bullish analysts highlighting specific growth drivers and valuation support while others keep a more measured stance on key oncology and I&I assets.
Aggiornamento della narrazione • May 28
GILD: HIV And Oncology Pipeline Expansion Will Drive Long Term Upside
Gilead Sciences' updated analyst price target edges up to $157.83 from $157.43, with analysts pointing to slightly higher modeled revenue growth, a modestly higher assumed future P/E of about 22.4x, and the growing contribution they see from assets like Trodelvy, Yeztugo and the Tubulis platform, even as views on long term oncology and I&I potential remain restrained. Analyst Commentary Analysts are split between those leaning into Gilead's newer growth drivers and those keeping a closer eye on execution risks and valuation.
Nuova narrazione • May 19
Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase
Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.
Aggiornamento della narrazione • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.Aggiornamento della narrazione • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.Aggiornamento della narrazione • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.Aggiornamento della narrazione • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.Aggiornamento della narrazione • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.Aggiornamento della narrazione • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.Aggiornamento della narrazione • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.Aggiornamento della narrazione • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.Aggiornamento della narrazione • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.Aggiornamento della narrazione • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.Aggiornamento della narrazione • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.Aggiornamento della narrazione • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.Aggiornamento della narrazione • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Aggiornamento della narrazione • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Aggiornamento della narrazione • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Aggiornamento della narrazione • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Articolo di analisi • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$9b |
| Dec 31 2025 | US$28m | US$2m | US$9b |
| Sep 30 2025 | n/a | n/a | US$8b |
| Jun 30 2025 | n/a | n/a | US$6b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$24m | US$2m | US$480m |
| Sep 30 2024 | n/a | n/a | US$126m |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$485m |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$5b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$4b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$5b |
| Mar 31 2021 | n/a | n/a | US$301m |
| Dec 31 2020 | US$19m | US$2m | US$123m |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | -US$257m |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$29m | US$1m | US$5b |
Compensazione vs Mercato: La retribuzione totale di Dan ($USD 28.44M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.56M ).
Compensazione vs guadagni: La retribuzione di Dan è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Dan O'Day (61 yo)
7.3yrs
Mandato
US$28,437,198
Compensazione
Mr. Daniel Patrick O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galap...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$28.44m | 0.050% $ 77.9m | |
| Executive VP & CFO | 6.6yrs | US$8.77m | 0.014% $ 21.5m | |
| Chief Commercial & Corporate Affairs Officer | 6.9yrs | US$9.30m | 0.010% $ 15.6m | |
| Chief Medical Officer | 1.4yrs | US$13.92m | 0.0015% $ 2.4m | |
| Senior VP | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Treasury & Investor Relations | 5.4yrs | Nessun dato | Nessun dato | |
| Executive VP | less than a year | Nessun dato | 0.00043% $ 668.2k | |
| Executive Vice President of Human Resources | 6.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Research | 6.3yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Research | 5.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Intercontinental Region & Global Patient Solutions | 6.1yrs | Nessun dato | Nessun dato | |
| VP of Oncology & Franchise Head of Early Development | no data | Nessun dato | Nessun dato |
6.1yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di GILD è esperto e expertise (durata media dell'incarico 6.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$28.44m | 0.050% $ 77.9m | |
| Lead Independent Director | 5.7yrs | US$479.96k | 0.0010% $ 1.6m | |
| Independent Director | 2.3yrs | US$409.92k | 0.00044% $ 683.7k | |
| Independent Director | 8.4yrs | US$429.92k | 0.0022% $ 3.4m | |
| Independent Director | 8.1yrs | US$432.44k | 0.0012% $ 1.9m | |
| Independent Director | 5.5yrs | US$409.78k | 0.00081% $ 1.3m | |
| Independent Director | 9.8yrs | US$437.44k | 0.00011% $ 170.9k | |
| Independent Director | 6yrs | US$409.92k | 0.0011% $ 1.7m | |
| Independent Director | 6.4yrs | US$433.94k | 0.00051% $ 792.5k |
6.4yrs
Durata media
71yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GILD sono considerati esperti (durata media dell'incarico 6.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/25 08:13 |
| Prezzo dell'azione a fine giornata | 2026/06/25 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Gilead Sciences, Inc. è coperta da 65 analisti. 24 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |